Sensus Healthcare to Participate in Two Upcoming September 2018 Investor Conferences

Sensus Healthcare, Inc. today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018

BOCA RATON, Fla., Aug. 27, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows:

    Annual B. Riley FBR Healthcare Conference

    Date:                                Tuesday, September 4, 2018

    Format:                             One-on-one meetings only

    Venue:                               New York Marriott East Side in
                                         New York City


    H.C. Wainwright 20th Annual Global Investment Conference

    Date:                               September 4-6, 2018

    Format:                             Company presentation

    Presentation:                        Thursday, September 6, 2018 at
                                         11:40 a.m. Eastern time

    Venue:                               St. Regis New York Hotel in New
                                         York City

Mr. Sardano's presentation at the H.C. Wainwright 20th Annual Global Investment Conference will be webcast live and available for replay in the Investor Relations section of the Company's website at sensushealthcare.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com

View original content:http://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-two-upcoming-investor-conferences-300702054.html

SOURCE Sensus Healthcare

   
Company Codes: NASDAQ-SMALL:SRTS  

MORE ON THIS TOPIC